根据ESI于2022年1月13日发布的数据,我校高被引论文(Highly Cited Papers)200篇,热点论文(Hot Papers)14篇,见附件:2022年1月yl23455永利高被引论文及热点论文简表。详情如下。
从学科角度看,在200篇高被引论文中,临床医学最多(101篇),占比50.50%,分子生物学与遗传学(20篇)第二,占比10.00%,生物学与生物化学17篇(8.50%)紧跟其后。
序号 |
2022年1月我校14篇热点论文 标题 |
来源期刊 |
DOI |
Research Field |
Times Cited |
1 |
CLINICAL CHARACTERISTICS OF CORONAVIRUS DISEASE 2019 IN CHINA |
NEW ENGLAND JOURNAL OF MEDICINE 382 (18): 1708-1720 APR 30 2020 |
10.1056/NEJMoa2002032 |
CLINICAL MEDICINE |
7979 |
2 |
COMORBIDITY AND ITS IMPACT ON 1590 PATIENTS WITH COVID-19 IN CHINA: A NATIONWIDE ANALYSIS |
EUROPEAN RESPIRATORY JOURNAL 55 (5): - MAY 1 2020 |
10.1183/13993003.00547-2020 |
CLINICAL MEDICINE |
636 |
3 |
DAPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE |
NEW ENGLAND JOURNAL OF MEDICINE 383 (15): 1436-1446 OCT 8 2020 |
10.1056/NEJMoa2024816 |
CLINICAL MEDICINE |
417 |
4 |
DEVELOPMENT AND VALIDATION OF A CLINICAL RISK SCORE TO PREDICT THE OCCURRENCE OF CRITICAL ILLNESS IN HOSPITALIZED PATIENTS WITH COVID-19 |
JAMA INTERNAL MEDICINE 180 (8): 1081-1089 AUG 2020 |
10.1001/jamainternmed.2020.2033 |
CLINICAL MEDICINE |
395 |
5 |
STRUCTURAL AND FUNCTIONAL PROPERTIES OF SARS-COV-2 SPIKE PROTEIN: POTENTIAL ANTIVIRUS DRUG DEVELOPMENT FOR COVID-19 |
ACTA PHARMACOLOGICA SINICA 41 (9): 1141-1149 SEP 2020 |
10.1038/s41401-020-0485-4 |
PHARMACOLOGY & TOXICOLOGY |
284 |
6 |
FERROPTOSIS: PAST, PRESENT AND FUTURE |
CELL DEATH & DISEASE 11 (2): - FEB 3 2020 |
10.1038/s41419-020-2298-2 |
MOLECULAR BIOLOGY & GENETICS |
263 |
7 |
SURVEY OF INSOMNIA AND RELATED SOCIAL PSYCHOLOGICAL FACTORS AMONG MEDICAL STAFF INVOLVED IN THE 2019 NOVEL CORONAVIRUS DISEASE OUTBREAK |
FRONTIERS IN PSYCHIATRY 11: - APR 14 2020 |
10.3389/fpsyt.2020.00306 |
PSYCHIATRY/PSYCHOLOGY |
191 |
8 |
THERAPEUTIC STRATEGIES FOR HEPATITIS B VIRUS INFECTION: TOWARDS A CURE |
NATURE REVIEWS DRUG DISCOVERY 18 (11): 827-844 NOV 2019 |
10.1038/s41573-019-0037-0 |
PHARMACOLOGY & TOXICOLOGY |
125 |
9 |
RAPID AND SENSITIVE DETECTION OF ANTI-SARS-COV-2 IGG, USING LANTHANIDE-DOPED NANOPARTICLES-BASED LATERAL FLOW IMMUNOASSAY |
ANALYTICAL CHEMISTRY 92 (10): 7226-7231 MAY 19 2020 |
10.1021/acs.analchem.0c00784 |
CHEMISTRY |
121 |
10 |
GUIDELINES FOR THE USE AND INTERPRETATION OF ASSAYS FOR MONITORING AUTOPHAGY (4TH EDITION) |
AUTOPHAGY 17 (1): 1-382 2021 |
10.1080/15548627.2020.1797280 |
MOLECULAR BIOLOGY & GENETICS |
106 |
11 |
THE PREVALENCE AND INFLUENCING FACTORS IN ANXIETY IN MEDICAL WORKERS FIGHTING COVID-19 IN CHINA: A CROSS-SECTIONAL SURVEY |
EPIDEMIOLOGY AND INFECTION 148: - 2020 |
10.1017/S0950268820001107 |
SOCIAL SCIENCES, GENERAL |
96 |
12 |
A MULTIFUNCTIONAL AMINATED UIO-67 METAL-ORGANIC FRAMEWORK FOR ENHANCING ANTITUMOR CYTOTOXICITY THROUGH BIMODAL DRUG DELIVERY |
CHEMICAL ENGINEERING JOURNAL 412: - MAY 15 2021 |
10.1016/j.cej.2020.127899 |
ENGINEERING |
26 |
13 |
SINTILIMAB PLUS A BEVACIZUMAB BIOSIMILAR (IBI305) VERSUS SORAFENIB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA (ORIENT-32): A RANDOMISED, OPEN-LABEL, PHASE 2-3 STUDY |
LANCET ONCOLOGY 22 (7): 977-990 JUL 2021 |
10.1016/S1470-2045(21)00252-7 |
CLINICAL MEDICINE |
14 |
14 |
PULSE THERAPY WITH VINCRISTINE AND DEXAMETHASONE FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA (CCCG-ALL-2015) AN OPEN-LABEL, MULTICENTRE, RANDOMISED, PHASE 3 NON-INFERIORITY TRIAL |
LANCET ONCOLOGY 22 (9): 1322-1332 SEP 2021 |
10.1016/S1470-2045(21)00328-4 |
CLINICAL MEDICINE |
6 |
周一至周日 8:00-22:00
周一至周日 8:00-22:00
电话:020-62789014(本部)
0757-29985219(顺德)
电话:020-61648543
电话:020-61648053
电话:020-62789012
电话:020-61648051
电话:020-62789012
邮政编码:510515
邮政编码:528305
当前IP地址:45.38.2.130